Xeris retires $33.5M of 2028 convertible notes via exchange and conversion

Xeris Biopharma Holdings, Inc.

Exchanged ~$23M principal of 8.00% Convertible Senior Notes due 2028 for ~5.0M shares and ~$23M cash.
Separately, a holder converted $10.5M principal into ~3.6M shares.
After transactions, no 2028 Notes remain outstanding; all cancelled.
Shares issued in exchange were unregistered, relying on Section 4(a)(2) exemption; conversion shares on Section 3(a)(9).
Company funded cash portion with liquidity on-hand.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.